BioStrand
a subsidiary of IPA

Introducing
LENS^{ai}™ Immunogenicity Screening

The future of immunogenicity screening

Introducing LENS^{ai} Integrated Intelligence Technology - an innovative platform that integrates advanced AI capabilities to provide unparalleled protein analysis and immunogenicity screening with lightning-fast throughput. LENS^{ai} Immunogenicity calculation combines HLA II binding and human proteome presence using BioStrand's proprietary HYFT® technology for early stage risk assessment.

High-throughput immunogenicity analysis

Built for high volume
Virtually limitless quantity can be screened, compared and ranked

Flexible implementation
Ability to integrate in your own pipelines and workflows

Detailed reporting
Massive data package made transparent and instantly usable



In-depth immunogenic profiling

Built for insight
- Detailed linkage between clone and target
- Geno- and phenotype binding distribution mapped to target indication profile

Connecting target, lead and clinical events
MHCII allele phenotypes and genotypes associated with clinical events



Service offered as yearly subscription or project-based.

Powering
Biotherapeutic
Intelligence

Introducing LENS^{ai} Immunogenicity Screening

Key features: unmatched throughput, speed, scalability, and accuracy

Reference your antibodies against a database of all therapeutic antibodies



Unparalleled multi-level analyses and comprehensive reporting



Immunogenicity composite scores of antibodies in the therapeutic structural Ab database (n ≈ 2000):

Parsed based on Nomenclature (n ≈ 260)
Statistical significance:
Significant difference between all means based on Kruksal-Wallis analysis [P-value: <0,0001]
Significant, Bonferonni corrected, difference between individual groups and Human (control group) based on Mann-Whitney [P-value: 0,0002 and better]

Immunogenic zones per sequence

Normalized score showing immunogenicity hotspots by combining HYFT Universal Fingerprint proteome screening and HLA II binding scores.

Dark Blue = 0 = low immunogenic potential
Dark Red = 100 = highest immunogenic potential

CDR annotations based on IMGT numbering



BioStrand
a subsidiary of IPA

Biostrand.ai

For more information contact: info@biostrand.ai